N Undevia-Yedavalli

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
e16083 Background: Growing numbers of prostate cancer patients experience biochemical relapse (PSA failure) after initial treatment. LhRH agonist (hormonal) therapy can reduce PSA levels, but there is no clear evidence that it slows disease progression or reduces mortality. Quality of Life (QoL) issues are essential when deciding between observation (OBS)(More)
  • 1